long-acting insulin substitutes." Last November, Novo Nordisk announced it would stop selling the injectable FlexPen version of Levemir this month and halt sales of Levemir vials by December 2024.

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...

If insulin glargine was prescribed ... a sole insulin analogue that could not be substituted with Innolet or FlexPen. Outcomes measures. Patient satisfaction. All patients completed a self ...